Nouscom SRL

Quick facts

Phase 1 pipeline

• GAd-209-FSP high dose
• GAd-209-FSP low dose
• GAd20-209-FSP, RP2D
• MVA-209-FSP high dose
• MVA-209-FSP low dose
• MVA-209-FSP, RP2D

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Nouscom SRL portfolio CI brief
• Nouscom SRL pipeline updates RSS